RA
Rosalind Advisors Portfolio holdings
AUM
$207M
This Quarter Return
+39.95%
1 Year Return
+62.29%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$120M
AUM Growth
–
Cap. Flow
+$120M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
62.88%
Holding
29
New
27
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Lyra Therapeutics
LYRA
|
$9.9M |
| 2 |
Myomo
MYO
|
$9.62M |
| 3 |
Astria Therapeutics
ATXS
|
$8.67M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$8.33M |
| 5 |
Viridian Therapeutics
VRDN
|
$7.85M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Lyra Therapeutics
LYRA
$11.5M
| $9.9M | 8.15% | +1,888,720 | New | +$9.9M |
|
|
2
Myomo
MYO
$39.7M
| $9.62M | 7.92% | +1,919,910 | New | +$9.62M |
|
|
3
Astria Therapeutics
ATXS
$349M
| $8.67M | 7.14% | +1,128,708 | New | +$8.67M |
|
|
4
Xeris Biopharma Holdings
XERS
$1.26B
| $8.33M | 6.86% | +3,543,685 | New | +$8.33M |
|
|
5
Viridian Therapeutics
VRDN
$1.5B
| $7.85M | 6.46% | +360,332 | New | +$7.85M |
|
|
CMPS
6
Compass Pathways
CMPS
$424M
| $6.99M | 5.75% | +798,500 | New | +$6.99M |
|
|
OPTN
7
DELISTED
OptiNose
OPTN
| $6.3M | 5.19% | +4,885,580 | New | +$6.3M |
|
8
MediWound
MDWD
$182M
| $6.17M | 5.08% | +606,751 | New | +$6.17M |
|
9
Madrigal Pharmaceuticals
MDGL
$9.76B
| $5.78M | 4.76% | +25,000 | New | +$5.78M |
|
10
Cellectar Biosciences
CLRB
$15.5M
| $5.56M | 4.58% | +2,005,658 | New | +$5.56M |
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $5.54M | 4.56% | +57,400 | New | +$5.54M |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $4.97M | 4.09% | +250,000 | New | +$4.97M |
|
|
SPRB
13
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $4.65M | 3.83% | +1,586,392 | New | +$4.65M |
|
|
PROF
14
Profound Medical
PROF
$134M
| $4.53M | 3.73% | +533,333 | New | +$4.53M |
|
15
Delcath Systems
DCTH
$385M
| $4.32M | 3.56% | +1,038,828 | New | +$4.32M |
|
16
KalVista Pharmaceuticals
KALV
$678M
| $3.68M | 3.03% | +300,000 | New | +$3.68M |
|
17
Veru
VERU
$47.6M
| $2.88M | 2.37% | +4,000,000 | New | +$2.88M |
|
18
InspireMD
NSPR
$102M
| $2.6M | 2.14% | +925,194 | New | +$2.6M |
|
19
Trevi Therapeutics
TRVI
$883M
| $2.5M | 2.06% | +1,862,425 | New | +$2.5M |
|
20
Ascendis Pharma
ASND
$11.8B
| $2.12M | 1.74% | +16,800 | New | +$2.12M |
|
21
Fortress Biotech
FBIO
$76.8M
| $1.83M | 1.51% | +607,797 | New | +$1.83M |
|
22
enVVeno Medical
NVNO
$15.4M
| $1.6M | 1.32% | +312,091 | New | +$1.6M |
|
23
Reviva Pharmaceuticals
RVPH
$30.6M
| $1.01M | 0.83% | +196,300 | New | +$1.01M |
|
|
MACK
24
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $805K | 0.66% | +60,000 | New | +$805K |
|
25
Talphera
TLPH
$11.1M
| $558K | 0.46% | +758,966 | New | +$558K |
|